A Prospective Longitudinal Study of Growth, Development, Fertility and Reproductive Outcomes Among Adolescents and Young Adults With Sickle Cell Anemia With Hydroxyurea
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Healthy Volunteers: f
View:
• Patients with documented sickle cell anemia (SCA).
• At least 8 years of age at the time of enrollment.
• Enrolled on the EXTEND or SACRED study.
• Provide informed consent.
• Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.
Locations
Other Locations
Dominican Republic
Centro de Obstetricia y Ginecologia
RECRUITING
Santo Domingo
Jamaica
Caribbean Institute for Health Research, University of West Indies
RECRUITING
Kingston
Contact Information
Primary
Teresa Latham, DrPh
Teresa.Latham@cchmc.org
513-803-7822
Backup
Russell E Ware, MD, PhD
Russell.Ware@cchmc.org
513-803-4597
Time Frame
Start Date: 2023-07-10
Estimated Completion Date: 2035-12-31
Participants
Target number of participants: 250
Treatments
Sickle Cell Anemia
Those with sickle cell anemia (SCA).
Related Therapeutic Areas
Sponsors
Collaborators: Caribbean Institute for Health Research, University of West Indies, Centro de Obstetricia y Ginecologia Recruiting Santo Domingo, Dominican Republic
Leads: Children's Hospital Medical Center, Cincinnati